☆ 4.7 Article

Effectiveness of COVID-19 vaccines on hospitalization and death in Guilan, Iran: a test-negative case-control study

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2023)

Related references

Note: Only part of the references are listed.

Article Immunology

Impact of the Sinopharm's BBIBP-CorV vaccine in preventing hospital admissions and death in infected vaccinees: Results from a retrospective study in the emirate of Abu Dhabi, United Arab Emirates (UAE)

Farida Ismail AlHosani et al.

Summary: This community-based observational study found that the BBIBP-CorV inactivated vaccine is effective in preventing severe COVID-19 outcomes such as hospital admissions and death. Fully vaccinated individuals showed higher protection compared to partially vaccinated individuals.

VACCINE (2022)

Add to Collection

Article Microbiology

Effectiveness of COVID-19 vaccines against symptomatic SARS-CoV-2 infection and severe outcomes with variants of concern in Ontario

Sharifa Nasreen et al.

Summary: The study conducted in Ontario, Canada, analyzed the effectiveness of BNT162b2 (Pfizer-BioNTech Comirnaty), mRNA-1273 (Moderna Spikevax), and ChAdOx1 (AstraZeneca Vaxzevria) vaccines against different variants of SARS-CoV-2. The findings suggest that two doses of the vaccines provide higher protection, and the effectiveness against hospitalization or death is similar to or higher than against symptomatic infection.

NATURE MICROBIOLOGY (2022)

Add to Collection

Review Medicine, General & Internal

Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis

Baoqi Zeng et al.

Summary: This study conducted a systematic review and meta-analysis to assess the effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern (VOC). The results showed that full vaccination was highly effective against the Alpha variant and moderately effective against the Beta, Gamma, and Delta variants. Booster vaccination was more effective against the Delta and Omicron variants. mRNA vaccines appeared to have higher effectiveness against the VOC compared to other vaccines.

BMC MEDICINE (2022)

Add to Collection

Article Immunology

Effectiveness of Coronavirus Disease 2019 Vaccines in Preventing Infection, Hospital Admission, and Death: A Historical Cohort Study Using Iranian Registration Data During Vaccination Program

Alireza Mirahmadizadeh et al.

Summary: The mass vaccination program in Iran has led to a significant reduction in COVID-19 infections, hospital admissions, and deaths associated with COVID-19.

OPEN FORUM INFECTIOUS DISEASES (2022)

Add to Collection

Article Infectious Diseases

Vaccine effectiveness against COVID-19 hospitalization in adults in France: A test negative case control study

Liem Binh Luong Ngyen et al.

Summary: We have confirmed the high effectiveness of the COVID-19 vaccine in France in preventing hospitalizations due to the alpha variant through data analysis from five hospitals.

INFECTIOUS DISEASES NOW (2022)

Add to Collection

Article Medicine, General & Internal

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Merryn Voysey et al.

Summary: The ChAdOx1 nCoV-19 vaccine has been shown to have an acceptable safety profile and effectiveness against symptomatic COVID-19, with higher efficacy observed in the group that received a low dose followed by a standard dose.

LANCET (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity

Wilfredo F. Garcia-Beltran et al.

Summary: New variants of SARS-CoV-2 show high resistance to vaccine neutralization, with some able to escape vaccine responses with just a few mutations, highlighting the importance of developing broadly protective measures against variants.

CELL (2021)

Add to Collection

Article Immunology

The Impact of Vaccination on Coronavirus Disease 2019 (COVID-19) Outbreaks in the United States

Seyed M. Moghadas et al.

Summary: The study evaluated the impact of a 2-dose COVID-19 vaccination campaign in the United States on reducing the incidence, hospitalizations, and deaths. Results showed that vaccination significantly reduced the overall attack rate, with the greatest reduction observed in individuals aged 65 and older. Additionally, vaccination markedly decreased the risk of non-ICU hospitalizations, ICU hospitalizations, and deaths.

CLINICAL INFECTIOUS DISEASES (2021)

Add to Collection

Editorial Material Medicine, General & Internal

SARS-CoV-2 Variants of Concern in the United States-Challenges and Opportunities

Rochelle P. Walensky et al.

Summary: The Viewpoint discusses the measures taken by federal agencies to rapidly characterize emerging coronavirus variants and monitor their implications for national pandemic response and control. This includes assessment of the ongoing effectiveness of current diagnostics, therapeutics, and vaccines.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

Add to Collection

Article Medicine, General & Internal

Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia

Denis Y. Logunov et al.

Summary: The Gam-COVID-Vac vaccine showed 91.6% efficacy against COVID-19 in the phase 3 trial, with good safety and tolerability in a large cohort of participants.

LANCET (2021)

Add to Collection

Article Medicine, General & Internal

Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study

Robert Challen et al.

Summary: The study found that the mortality hazard ratio associated with infection with VOC-202012/1 compared with previously circulating variants was 1.64, indicating an increase in deaths from 2.5 to 4.1 per 1000 detected cases in comparatively low risk group of covid-19 patients in the community. This suggests that infection with VOC-202012/1 may lead to substantial additional mortality compared with previously circulating variants, impacting healthcare capacity planning and control policies.

BMJ-BRITISH MEDICAL JOURNAL (2021)

Add to Collection

Article Biochemistry & Molecular Biology

SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies

Markus Hoffmann et al.

Summary: The emerging SARS-CoV-2 variants may exhibit resistance to existing neutralizing antibodies and treatments, which could have significant implications for pandemic containment efforts.

CELL (2021)

Add to Collection

Article Medicine, General & Internal

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial

Katherine R. W. Emary et al.

Summary: A post-hoc analysis was conducted on the efficacy of the ChAdOx1 nCoV-19 vaccine against the B.1.1.7 variant of SARS-CoV-2 in the UK. The vaccine showed reduced neutralisation activity against the B.1.1.7 variant in vitro, but still demonstrated efficacy against the B.1.1.7 variant of the virus.

LANCET (2021)

Add to Collection

Letter Medicine, General & Internal

Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants

Laith J. Abu-Raddad et al.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant

V. Shinde et al.

Summary: The NVX-CoV2373 vaccine showed efficacy in preventing Covid-19, with higher vaccine efficacy observed among HIV-negative participants. Most infections were caused by the B.1.351 variant.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Public, Environmental & Occupational Health

E-health roadmap for COVID-19 vaccine coverage in Iran

Elham Maserat et al.

Summary: The study developed a multidimensional e-health roadmap for responding to the Covod-19 pandemic and investigating the role of IT in improving vaccine distribution in Iran. The technology-based roadmap went through a two-stage Delphi method process, involving 14 e-health experts to confirm 4 conceptual models for vaccine distribution stages.

BMC PUBLIC HEALTH (2021)

Add to Collection

Article Medicine, General & Internal

Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults A Randomized Clinical Trial

Nawal Al Kaabi et al.

Summary: This interim analysis of an ongoing randomized trial in the UAE and Bahrain evaluated the efficacy of two inactivated COVID-19 vaccines in preventing symptomatic cases and adverse events in healthy adults. The study found that both vaccines significantly reduced the risk of symptomatic COVID-19 compared to the control group, with efficacy rates of 72.8% and 78.1%. Serious adverse events were rare across all groups.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

Add to Collection

Article Multidisciplinary Sciences

Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization

Delphine Planas et al.

Summary: The SARS-CoV-2 B.1.617 Delta variant, first identified in India in 2020, has become dominant in some regions and is spreading to many countries. This variant shows resistance to certain monoclonal antibodies and antibodies in convalescent sera, as well as reduced neutralization by some COVID-19 vaccines. Administration of two doses of the vaccine is needed for a neutralizing response against the Delta variant.

NATURE (2021)

Add to Collection

Article Environmental Sciences

COVID-19 Vaccines Safety Tracking (CoVaST): Protocol of a Multi-Center Prospective Cohort Study for Active Surveillance of COVID-19 Vaccines' Side Effects

Abanoub Riad et al.

Summary: This study aims to actively monitor the safety and effectiveness of COVID-19 vaccines globally in three phases, including short-term side effects, booster doses' side effects, and long-term safety and effectiveness. The protocol has been registered on ClinicalTrials.gov, with the identifier NCT04834869.

INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH (2021)

Add to Collection

Review Public, Environmental & Occupational Health

Test-Negative Designs Differences and Commonalities with Other Case-Control Studies with Other Patient Controls

Jan P. Vandenbroucke et al.

EPIDEMIOLOGY (2019)

Add to Collection

Review Immunology

Case-control vaccine effectiveness studies: Preparation, design, and enrollment of cases and controls

Jennifer R. Verani et al.

VACCINE (2017)

Add to Collection

Article Immunology

The test-negative design for estimating influenza vaccine effectiveness

Michael L. Jackson et al.

VACCINE (2013)

Add to Collection

Review Microbiology

Real-time PCR in clinical microbiology: Applications for a routine laboratory testing

MJ Espy et al.

CLINICAL MICROBIOLOGY REVIEWS (2006)

Add to Collection

© Peeref 2019-2024. All rights reserved.